Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments

BACKGROUND: The introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) into clinical practice has dramatically improve the clinical outcomes of individuals with rheumatoid arthritis (RA). However, bDMARDs are associated with high costs, which has resulted in restricted treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashiri, Shin-ya, Shimizu, Toshimasa, Sato, Shuntaro, Morimoto, Shimpei, Kawazoe, Yurika, Sumiyoshi, Remi, Hosogaya, Naoki, Fukushima, Chizu, Yamamoto, Hiroshi, Kawakami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387067/
https://www.ncbi.nlm.nih.gov/pubmed/32791688
http://dx.doi.org/10.1097/MD.0000000000021151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387067/
https://www.ncbi.nlm.nih.gov/pubmed/32791688
http://dx.doi.org/10.1097/MD.0000000000021151

Ejemplares similares